Randomized, Double-Blind Phase 2 Study of Axitinib (AG-013736) With Or Without Dose Titration In Patients With Metastatic Renal Cell Carcinoma

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Overall Response Rate

Outcome Time Frame:

3 years

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A4061046

NCT ID:

NCT00835978

Start Date:

August 2009

Completion Date:

September 2013

Related Keywords:

• Carcinoma, Renal Cell
• axitinib or AG-013736 dose titration (increase) renal cell carcinoma
• kidney cancer
• Carcinoma
• Carcinoma, Renal Cell
• Kidney Neoplasms